RAPT Therapeutics (RAPT) Competitors

RAPT Therapeutics (NASDAQ:RAPT) and Editas Medicine (NASDAQ:EDIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, community ranking, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Which has more risk & volatility, RAPT or EDIT?

RAPT Therapeutics has a beta of -0.31, suggesting that its stock price is 131% less volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.

Does the media refer more to RAPT or EDIT?

In the previous week, Editas Medicine had 1 more articles in the media than RAPT Therapeutics. MarketBeat recorded 3 mentions for Editas Medicine and 2 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 0.93 beat Editas Medicine's score of 0.68 indicating that RAPT Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RAPT Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Editas Medicine	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate RAPT or EDIT?

RAPT Therapeutics presently has a consensus price target of $5.29, indicating a potential upside of 380.52%. Editas Medicine has a consensus price target of $6.83, indicating a potential upside of 288.26%. Given RAPT Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe RAPT Therapeutics is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RAPT Therapeutics	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Editas Medicine	2 Sell rating(s)	9 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.07

Does the MarketBeat Community prefer RAPT or EDIT?

Editas Medicine received 223 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. However, 62.94% of users gave RAPT Therapeutics an outperform vote while only 53.23% of users gave Editas Medicine an outperform vote.

Company	Underperform	Outperform
RAPT Therapeutics	Outperform Votes 90 62.94%	Underperform Votes 53 37.06%
Editas Medicine	Outperform Votes 313 53.23%	Underperform Votes 275 46.77%

Do institutionals and insiders believe in RAPT or EDIT?

99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Which has stronger earnings & valuation, RAPT or EDIT?

RAPT Therapeutics has higher earnings, but lower revenue than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RAPT Therapeutics	$1.53M	25.13	-$116.80M	-$2.77	-0.40
Editas Medicine	$61.76M	2.35	-$153.22M	-$2.56	-0.69

Is RAPT or EDIT more profitable?

RAPT Therapeutics has a net margin of 0.00% compared to Editas Medicine's net margin of -340.96%. Editas Medicine's return on equity of -80.13% beat RAPT Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RAPT Therapeutics	N/A	-89.10%	-76.13%
Editas Medicine	-340.96%	-80.13%	-50.99%

Summary

RAPT Therapeutics beats Editas Medicine on 10 of the 18 factors compared between the two stocks.